Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Paclitaxel or its derivativesPDL I DEC / 13
Palbociclib or its saltsPDL I AUG / 16
PaliferminPDL I DEC / 13
Paliperidone or its salts or its derivativesPDL I DEC / 13
PalivizumabPDL I DEC / 13
Palonosetron or its saltsPDL

including but not limited to palonosetron hydrochloride

I DEC / 13
Pamidronic acid or its saltsPDL I DEC / 13
Pancreatic extractsPDL

when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

I DEC / 13
PancreatinPDL

when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

I DEC / 13
PancrelipasePDL

when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

I DEC / 13
Pancuronium or its saltsPDL I DEC / 13
PanitumumabPDL I DEC / 13
Pantoprazole or its saltsPDL I DEC / 13
Papaveretrine or its salts I SEP / 98
Papaverine or its salts I SEP / 98
ParaldehydePDL I DEC / 13
ParamethadionePDL I DEC / 13
Pargyline or its saltsPDL I DEC / 13
ParicalcitolPDL I DEC / 13
Paritaprevir (Veruprevir)PDL I MAR / 15
Paroxetine or its saltsPDL I DEC / 13
Paroxypropione II SEP / 98
Pasireotide or its saltsPDL I DEC / 13
Patiromer sorbitex calciumPDL I NOV / 18
Patisiran or its saltsPDL I JUL / 19
Pazopanib or its saltsPDL I DEC / 13
Pegaptanib or its saltsPDL I DEC / 13
PegaspargasePDL I APR / 17
PegfilgrastimPDL I DEC / 13
PegvisomantPDL I DEC / 13
PembrolizumabPDL I JUN / 15
Pemetrexed or its saltsPDL I DEC / 13
Pemoline and any salts thereofC4 I JAN / 03
Penciclovir or its saltsPDL I DEC / 13
PenicillaminePDL I DEC / 13
Penicillin or its salts or derivativesPDL

Including but not limited to:
Amoxicillin, ampicillin, azlocillin, benzathine penicillin, carbenicillin, cloxacillin, dicloxacillin, hetacillin, mecillinam, methicillin, mezlocillin, nafcillin, oxacillin, ticarcillin, penicillin G (benzyl penicillin), procaine penicillin G.
 

I DEC / 18
Pentaerythritol tetranitrate I SEP / 98
Pentagastrin and its salts II SEP / 98
Pentamidine or its saltsPDL I DEC / 13
PentazocineN I JUN / 02
PentobarbitalC1 I JUN / 02
Pentolinium tartratePDL I DEC / 13
Pentosan polysulfate or its saltsPDL I DEC / 13
Pentostatin or its saltsPDL I DEC / 13
Pentoxifylline or its saltsPDL I DEC / 13
Peramivir or its salts or derivativesPDL I MAR / 17
PerampanelPDL I DEC / 13
PerflutrenPDL I DEC / 13
Pergolide or its saltsPDL I DEC / 13
Pericyazine or its saltsPDL I DEC / 13
Perindopril or its saltsPDL I DEC / 13
Permethrin and its derivatives II SEP / 98
Permethrin or its derivativesPDL

For veterinary use, when recommended in cats.

I DEC / 13
Perphenazine or its saltsPDL I DEC / 13
Pertussis vaccine II DEC / 98
PertuzumabPDL I DEC / 13
PethidineN I JUN / 02
Pethidine Intermediate CN I JUN / 02
Phacetoperane or its saltsPDL I DEC / 13
PhenacemidePDL I DEC / 13
PhenacetinPDL I DEC / 13
PhenadoxoneN I JUN / 02
PhenaglycodolPDL I DEC / 13
PhenampromideN I JUN / 02
PhenazocineN I JUN / 02
Phenazopyridine or its saltsPDL I DEC / 13
PhencyclidineN I JUN / 02
Phendimetrazine and any salt thereofC1 I JUN / 02
Phenelzine or its saltsPDL I DEC / 13
Phenformin and its saltsPDL I DEC / 13
Pheniprazine or its saltsPDL I DEC / 13
Pheniramine U
Phenmetrazine and any salt thereofC1 I JUN / 02
PhenobarbitalC2 I JUN / 02
Phenol preparations with concentration of more than 20% II SEP / 98
PhenomorphanN I JUN / 02
PhenoperidineN I JUN / 02
Phenoxybenzamine and its salts II SEP / 98
Phentermine and any salt thereofC2 I JUN / 02
Phenthoxate or its saltsPDL I DEC / 13
Phentolamine or its saltsPDL I DEC / 13
Phenylbutazone or its saltsPDL I DEC / 13
Phenylbutyric acid or its salts or derivativesPDL

Including but not limited to glycerol phenylbutyrate, phenylbutyrate sodium.

I AUG / 16
Phenylephrine and its salts and preparations in nasal preparations in concentrations of 2.5% or less, for pediatric use II SEP / 98
Phenylephrine and its salts and preparations. for oral use, in nasal preparations for adults and in ophthalmic preparations in concentrations of 2.5% or less U
Phenylephrine or its saltsPDL

In preparations for parenteral use or ophthalmic use in concentrations greater than 2.5%.

I DEC / 13
Phenylindanedione or its derivativesPDL I DEC / 13
Phenylmethylbarbituric AcidC2 I JUN / 02
Phenylpropanolamine or its salts or derivativesPDL I DEC / 13
Phenyltoloxamine and its salts III SEP / 98
PholcodineN I JUN / 02
Physostigmine salicylatePDL

For human use - except preparations for oral or topical use only.

I DEC / 13
Physostigmine salicylate.

for oral or topical use

II SEP / 98
Phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids.*PDL

except:
1) derivatives of cannabis as defined in subsection 2(1) of the Cannabis Act that are exempt from the application of the Cannabis Act under the Industrial Hemp Regulations and that do not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid, or

2) anything referred to in Schedule 2 to the Cannabis Act that contains no more than 10 µg/g delta-9-tetrahydrocannabinol and that does not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid.

*Note: this listing is copied from the Health Canada Prescription Drug List and applies to products that have received a Notice of Compliance and Drug Identification Number and been classified as prescription drugs by Health Canada. Cannabis products, as defined in the Cannabis Act and its regulations, are not granted a Notice of Compliance and Drug Identification Number by Health Canada and are considered outside the scope of the National Drug Schedules.

I OCT / 18
PibrentasvirPDL I SEP / 17
Pilocarpine or its saltsPDL I DEC / 13
PimecrolimusPDL I DEC / 13
PiminodineN I JUN / 02
PimobendanPDL I DEC / 13
PimozidePDL I DEC / 13
Pinaverium bromidePDL I DEC / 13
PinazepamTS I JUN / 02
Pindolol or its saltsPDL I DEC / 13
Pioglitazone or its saltsPDL I DEC / 13
Pipecuronium bromidePDL I DEC / 13
Piperacetazine or its saltsPDL I DEC / 13
Piperazine and its salts II SEP / 98
Piperilate or its saltsPDL I DEC / 13
PipobromanPDL I DEC / 13
Pipotiazine or its saltsPDL I DEC / 13
Pipradol and any salt thereofTS I SEP / 98
Pirbuterol or its saltsPDL I DEC / 13
Pirenzepine or its saltsPDL I DEC / 13
Pirfenidone or its derivativesPDL I DEC / 13
Pirlimycin or its saltsPDL I DEC / 13
Piroxicam or its saltsPDL I DEC / 13
Pizotyline or its saltsPDL I DEC / 13
Plecanatide PDL I NOV / 19
Plerixafor or its saltsPDL I DEC / 13
Pneumococcal 7-valent conjugate vaccine II JAN / 04
Pneumococcal polysaccharide vaccines II FEB / 02
PodophyllotoxinPDL

When recommended for topical use.

I DEC / 13
PolidocanolPDL

When indicated for administration by injection.

I JAN / 16
Poliomyelitis vaccine II DEC / 98
Polyacrylamide II SEP / 98
Polyethylene glycol topical administration U
Polyethylene glycol 3350 as a single ingredient oral product indicated as a laxative to treat occasional constipation U JUL / 10
Polymyxin B or its salts or derivativesPDL

For human use - except for topical use or for local action in the oral cavity or nasal passages.

I DEC / 13
Polymyxin B or its salts or derivatives.PDL

For veterinary use - when sold in combination with other medicinal ingredients.

I APR / 16
Polymyxin B or its salts or derivatives..

for human, ophthalmic use

III JUN / 06
Polymyxin or its salts or derivatives for human, topical use U
Polysulfated glycosaminoglycanPDL I DEC / 13
Pomalidomide or its saltsPDL I FEB / 14
Ponatinib or its saltsPDL I MAY / 15
Poractant alfaPDL I DEC / 13
Porfimer or its saltsPDL I DEC / 13
PosaconazolePDL I DEC / 13
Potassium bromidePDL I DEC / 13
Potassium citratePDL

When recommended for the treatment of renal tubular acidosis and kidney stones.

I DEC / 13
Potassium gluconatePDL

For veterinary use - when sold or recommended for administration to cats.

I DEC / 13
Potassium para-aminobenzoatePDL

Except in preparations for topical use on the skin.

I DEC / 13
Potassium salts

In preparations for injection.

I DEC / 99
Potassium salts. in oral preparations containing more than 5 mmol per single dose [except potassium bromide, potassium gluconate when sold or recommended for administration to cats, potassium para-aminobenzoate, potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones] II DEC / 13
Povidone - iodine vaginal preparations, except in concentrations of 5% or less II SEP / 98
Pradofloxacin or their salts or derivativesPDL I MAR / 15
Pralatrexate or its saltsPDL I DEC / 18
Pralidoxime or its saltsPDL I DEC / 13
Pramipexole or its saltsPDL I DEC / 13
Pramoxine and its salts for ophthalmic or parenteral use II SEP / 98
Pramoxine and its salts.

for topical use on mucous membranes, except lozenges

III SEP / 98
Pramoxine and its salts.. for topical application on the skin, and including lozenges U DEC / 05
PrasteroneC3 I JUN / 02
Prasugrel or its saltsPDL I DEC / 13
Pravastatin or its saltsPDL I DEC / 13
Prazepam and its saltsTS I SEP / 98
PraziquantelPDL

For human use.

I DEC / 13
PraziquantelPDL

For veterinary use - except when sold for the treatment of the tapeworm Anoplocephala perfoliata in horses.

I DEC / 13
Prazosin or its saltsPDL I DEC / 13
Pregabalin or its salts or derivativesPDL I DEC / 13
Prenylamine or its saltsPDL I DEC / 13
Prilocaine and its salts

for ophthalmic or parenteral use

II SEP / 98
Prilocaine and its salts.

for topical use on mucous membranes, except lozenges

III SEP / 98
Primaquine or its saltsPDL I DEC / 13
PrimidonePDL

For human use.

I DEC / 13
ProbarbitalC2 I JUN / 02
Probenecid or its saltsPDL I DEC / 13
ProbucolPDL I DEC / 13
Procainamide or its saltsPDL I DEC / 13
Procaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
Procaine and its salts for ophthalmic or parenteral use II SEP / 98
Procarbazine or its saltsPDL I DEC / 13
Procaterol or its saltsPDL I DEC / 13
Prochlorperazine or its saltsPDL I DEC / 13
Procyclidine or its saltsPDL I DEC / 13
Prodilidine or its saltsPDL I DEC / 13
Profenamine or its saltsPDL

Including but not limited to ethopropazine.

I DEC / 13
Progesterone or its derivativesPDL

For veterinary use - except when recommended for use in progesterone implants indicated for growth promotion, melengestrol acetate in feed for the suppression of estrus in beef heifers.

I DEC / 13
Proguanil or its saltsPDL I DEC / 13
ProheptazineN I JUN / 02
Promazine or its saltsPDL

For human use.

I DEC / 13
Promethazine and its salts except for topical use II SEP / 98
Promethazine and its salts for topical use III SEP / 98
Propafenone or its saltsPDL I DEC / 13
PropallylonalC2 I JUN / 02
Propantheline and its salts II SEP / 98
Proparacaine and its salts for ophthalmic or parenteral use II SEP / 98
Proparacaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
ProperidineN I JUN / 02
PropiramN I JUN / 02
Propiverine or its saltsPDL I MAR / 17
PropofolPDL I DEC / 13
Propranolol or its saltsPDL I DEC / 13
Propylene glycol topical application U
Propylhexedrine II SEP / 98
Proquamezine [aminopromazine] and its salts

For internal use.

I SEP / 98
Prostaglandins or their salts or derivatives or analoguesPDL

Including but not limited to: Alprostadil, bimatoprost, cloprostenol, dinoprostone, epoprostenol, fluprostenol, latanoprost, latanoprostene bunod, lubiprostone, misoprostol, tafluprost, travoprost, treprostinil, unoprostone.

I AUG / 15
Protamine and its salts II SEP / 98
Prothipendyl hydrochloridePDL I DEC / 13
ProtirelinPDL I DEC / 13
Protriptyline or its saltsPDL I DEC / 13
Prucalopride or its saltsPDL

Including but not limited to prucalopride succinate.

I DEC / 13
Pseudoephedrine and its salts and preparations in combination products Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, pseudoephedrine products should not be located in a self-selection area of the pharmacy III APR / 06
Pseudoephedrine and its salts and preparations in single entity products II APR / 06
Pyrantel and its salts II SEP / 98
PyrazinamidePDL I DEC / 13
Pyrethrins II SEP / 98
Pyrethrins/piperonyl butoxide II SEP / 98
Pyridostigmine bromidePDL I DEC / 13
Pyrilamine U
Pyrimethamine or its saltsPDL I DEC / 13
Pyrovalerone and any salt thereofC4 I JAN / 03
Pyrvinium and its salts II SEP / 98
p-FluorofentanylN I JUN / 02

213 result(s)

Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled